The company, a clinical-stage biopharmaceutical firm, will participate in the Piper Sandler 37th Annual Healthcare Conference in December 2025. The company is focused on developing novel therapies for metabolic and endocrine disorders. An industry prediction suggests the mid-cap biotech could become a notable player in the industry's hottest therapeutic area and that this undervalued stock has the potential to compete with a major industry leader by 2029.